Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables

被引：0

作者：

Megias-Vericat, Juan Eduardo ^{[1
,2
]}

Marques, Maria Remedios ^{[1
]}

Haya, Saturnino ^{[3
]}

Cid, Ana Rosa ^{[3
]}

Querol, Felipe ^{[3
]}

Monte, Emilio ^{[1
,3
]}

Garcia-Dasi, Maria ^{[3
]}

Caunedo, Patricia ^{[3
]}

Vila, Carmen ^{[3
]}

Bosch, Pau ^{[3
]}

Curats, Rafael ^{[3
]}

Sanz, Miguel Angel ^{[4
]}

Poveda, Jose Luis ^{[1
,2
]}

Bonanad, Santiago ^{[5
]}

机构：

[1] Hosp Univ & Politecn La Fe, Dept Pharm, Drug Clin Area, Valencia, Spain

[2] Inst Invest Sanit La Fe, Valencia, Spain

[3] Hosp Univ & Politecn La Fe, Dept Hematol, Hemostasis & Thrombosis Unit, Valencia, Spain

[4] Hosp Univ & Politecn La Fe, Dept Hematol, Valencia, Spain

[5] Hosp La Ribera, Alzira, Spain

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.3802.3802

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3802

引用

页数：4

共 50 条

[21] Haematuria in a young patient with severe haemophilia and inhibitor presence receiving prophylactic treatment with recombinant factor VIIa
Economou, Marina
Papadopoulou, Eleni
Vagianou, Isidora
Farmaki, Evaggelia
Gompakis, Nikolaos
Athanassiou-Metaxa, Miranda
BLOOD COAGULATION & FIBRINOLYSIS, 2010, 21 (06) : 611 - 613
[22] Recombinant porcine factor VIII use in bleed treatment in non-severe haemophilia A inhibitor patients: Dosing strategies and efficacy
Ellsworth, Patrick
Chen, Sheh-Li
Key, Nigel
Abajas, Yasmina
Ma, Alice
HAEMOPHILIA, 2021, 27 (01) : E147 - E150
[23] The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A
Lusher, JM
Lee, CA
Kessler, CM
Bedrosian, CL
HAEMOPHILIA, 2003, 9 (01) : 38 - 49
[24] Recombinant factor VIII half life using a bayesian model in patients with severe haemophilia A on prophylaxis in Turkey
Albayrak, C.
Albayrak, D.
HAEMOPHILIA, 2019, 25 : 64 - 64
[25] Satisfaction Of Young Adults With Haemophilia A Previously Treated With Prophylaxis And Switching To Prophylactic Treatment With Recombinant Factor VIII Turoctocog Alfa
Ozelo, M.
Regnault, A.
Slothuus, U.
Hoxer, C. S.
HAEMOPHILIA, 2015, 21 : 66 - 67
[26] Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A
Kulkarni, Roshni
Ragni, Margaret V.
Baker, Ross I.
Pasi, John
Manco-Johnson, Marilyn J.
Potts, James
Brennan, Aoife
Pierce, Glenn F.
HAEMOPHILIA, 2014, 20 : 94 - 94
[27] Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A
Konkle, Barbara A.
Stasyshyn, Oleksandra
Chowdary, Pratima
Bevan, David H.
Mant, Tim
Shima, Midori
Engl, Werner
Dyck-Jones, Jacqueline
Fuerlinger, Monika
Patrone, Lisa
Ewenstein, Bruce
Abbuehl, Brigitt
BLOOD, 2015, 126 (09) : 1078 - 1085
[28] COST-EFFECTIVENESS ANALYSIS OF DIFFERENT RECOMBINANT FACTOR VIII FOR PROPHYLACTIC TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIAA IN CHINA
Yang, L.
Peng, J.
Gu, C.
Wang, Z.
Zuo, G.
VALUE IN HEALTH, 2024, 27 (12)
[29] Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A
Scharrer, I
Brackmann, HH
Sultan, Y
Abshire, T
Gazengel, C
Ragni, M
Gorina, E
Vosburgh, E
Kellermann, E
HAEMOPHILIA, 2000, 6 (06) : 614 - 618
[30] Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A
Tiede, Andreas
Rosa Cid, Ana
Goldmann, Georg
Jimenez-Yuste, Victor
Pluta, Michael
Lissitchkov, Toshko
May, Marcus
Matytsina, Irina
Miljic, Predrag
Pabinger, Ingrid
Persson, Paula
THROMBOSIS AND HAEMOSTASIS, 2020, 120 (02) : 277 - 288

← 1 2 3 4 5 →